[HTML][HTML] Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer
C Zhang, J Wang, X Wang, Z Meng… - Cancer Biology & …, 2022 - ncbi.nlm.nih.gov
Objective: In the phase II ALTER-1202 (NCT03059797) trial, anlotinib significantly improved
progression-free survival (PFS) and overall survival (OS) in patients with advanced small …
progression-free survival (PFS) and overall survival (OS) in patients with advanced small …
Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib
B Qin, L Xin, Q Hou, B Yang, J Zhang, X Qi… - Cancer …, 2021 - Wiley Online Library
Background Anlotinib significantly extended progression‐free survival (PFS) and overall
survival (OS) in small‐cell lung cancer (SCLC) as third or later line treatment. Methods In this …
survival (OS) in small‐cell lung cancer (SCLC) as third or later line treatment. Methods In this …
Effectiveness and safety of anlotinib monotherapy for patients with extensive-stage small-cell lung cancer who progressed to chemotherapy: A real-world exploratory …
Y Li, Z Sun, W Sun, H Wang… - Clinical Medicine Insights …, 2022 - journals.sagepub.com
Background: Anlotinib demonstrated promising efficacy for patients with extensive-stage
small-cell lung cancer (ES-SCLC) in clinical trials. However, the real-world evidence of …
small-cell lung cancer (ES-SCLC) in clinical trials. However, the real-world evidence of …
Inflammation‐based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy
T Chen, M Tang, X Xu, G Liang, Z Xiang… - Journal of Clinical …, 2022 - Wiley Online Library
Background According to the randomized multicenter phase II trial (ALTER1202), anlotinib
has been approved as a third‐line therapy for advanced small‐cell lung cancer (SCLC) …
has been approved as a third‐line therapy for advanced small‐cell lung cancer (SCLC) …
[HTML][HTML] Efficacy and safety of Anlotinib in the treatment of small cell Lung Cancer: A Real-World Observation Study
J Yuan, F Cheng, G Xiao, X Wang, H Fan - Frontiers in Oncology, 2022 - frontiersin.org
Aims: This study aimed to observe the efficacy and safety of anlotinib in the treatment of
small cell lung cancer (SCLC) in the real world, as first-line maintenance therapy, second …
small cell lung cancer (SCLC) in the real world, as first-line maintenance therapy, second …
P2. 12-11 quality of life in ALTER1202 Trial of Anlotinib as third-or further line therapy for advanced small cell lung Cancer (SCLC): a post-hoc analysis
K Li, Y Cheng, Q Wang, J Shi, B Han, L Wu… - Journal of Thoracic …, 2019 - jto.org
Background Anlotinib significantly improved progress-free survival of advanced small cell
lung cancer (SCLC) patients in ALTER1202 trial. In this post-hoc analysis, we assessed the …
lung cancer (SCLC) patients in ALTER1202 trial. In this post-hoc analysis, we assessed the …
[HTML][HTML] Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib
J Liu, S Li, S Zhang, C Yang, L Zhang… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
Background Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor
angiogenesis which has shown activity in several malignancies and approved for the …
angiogenesis which has shown activity in several malignancies and approved for the …
Anlotinib vs placebo as third-or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study
Y Cheng, Q Wang, K Li, J Shi, Y Liu, L Wu… - British Journal of …, 2021 - nature.com
Background This study aimed to evaluate the efficacy and safety of anlotinib as a third-line
and subsequent treatment for patients with small cell lung cancer (SCLC). Methods We …
and subsequent treatment for patients with small cell lung cancer (SCLC). Methods We …
Anlotinib as third-or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
J Shi, Y Cheng, Q Wang, K Li, L Wu, B Han, G Chen… - Frontiers of …, 2022 - Springer
Patients with small-cell lung cancer (SCLC) relapse within months after completing previous
therapies. This study aimed to investigate the efficacy and safety of anlotinib as third-or …
therapies. This study aimed to investigate the efficacy and safety of anlotinib as third-or …
[PDF][PDF] The efficacy and safety of anlotinib in extensive-stage small cell lung cancer: a multicenter real-world study
HR Zheng, AM Jiang, H Gao, N Liu… - Cancer Management …, 2022 - Taylor & Francis
Purpose Anlotinib, an antiangiogenic multi-target tyrosine kinase inhibitor (TKI), has shown
favorable anticancer efficacy and acceptable safety in treating extensive-stage small cell …
favorable anticancer efficacy and acceptable safety in treating extensive-stage small cell …
